Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels

Abstract

C-Mpl and PRV-1 expression was measured in a cohort of 48 patients with essential thrombocythemia (ET). A retrospective analysis was conducted to asses whether the presence of one or both markers correlates with a higher risk of developing thromboembolic complications. In this cohort, PRV-1 overexpression was associated with a significantly increased risk of thrombosis, whereas decreased c-Mpl expression was not. The results of this retrospective analysis must now be corroborated in a large, prospective trial of newly diagnosed patients.